CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 11, 2005, Pages 1434-1439

  Chen, Yi Qiang ^a   Shi, Huan Zhong ^a   Qin, Xue Jun ^a   Mo, Wu Ning ^a   Liang, Xiang Dong ^a   Huang, Ze Xin ^a   Yang, Hai Bo ^a   Wu, Cong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

CD4+CD25+ T cells; Lung cancer; Pleural effusion; Regulatory T lymphocyte

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CYTOTOXIC LYMPHOCYTE ASSOCIATED ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR FOXP3; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CARCINOMA; LUNG LAVAGE; LYMPHOCYTE FUNCTION; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RECEPTORS, INTERLEUKIN-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 30344474268     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200504-588OC     Document Type: Article

References (39)

1. Sahn SA. State of the art: the pleura. Am Rev Respir Dis 1988;138:184-234.
2. Light RW. Pleural effusion. N Engl J Med 2002;346:1971-1977.
3. Weissler JC, Nicod LP, Toews GB. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987;135:1353-1357.
4. Blanchard DK, Kavanagh JJ, Sinkovics JG, Cavanagh D, Hewitt SM, Djeu JY. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res 1988;48:6321-6327.
5. Hausher F, Yabro JW. Diagnosis and treatment of malignant pleural effusions. Semin Oncol 1985;12:54-75.
6. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
7. Lucivero G, Pierucci G, Bonomo L. Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J 1988;1:337-340.
8. Takahashi K, Sone S, Kimura S, Ogura T, Monden Y. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 1993;103:1732-1738.
9. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999;59:3128-3133.
10. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
11. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
12. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004;16:157-162.
13. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
14. + regulatory T lymphocytes in allergy and asthma. Allergy 2005;60:986-995.
15. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res 2002;62:5267-5272.
16. + regulatory T-cell levels in patients with melanoma. Clin Cancer Res 2003;9:2551-2559.
17. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
18. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772.
19. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-1762.
20. + lymphocytes in pleural cavity of patients with non-small cell lung cancer. Thorax 2001;56:639-642.
21. Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003;19:165-168.
22. + regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
23. + T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-1294.
24. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
25. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005;28:120-128.
26. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-190.
27. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
28. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 2004;172:5213-5221.
29. Qin XJ, Shi HZ, Huang ZX, Kang LF, Mo WN, Wu C. Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J 2005;25:605-611.
30. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-344.
31. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
32. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-822.
33. + regulatory T cells. Nat Immunol 2003;4:330-336.
34. + T regulatory cells. Nat Immunol 2003;4:337-342.
35. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
36. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 2005;65:1577-1586.
37. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
38. + T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
39. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618.